ReviewSurgical neurology international2026
The progress of tuberculous meningitis medical management in adults.
Review in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculous meningitis (TBM) is the most common central nervous system (CNS) infection caused by " Methods: This literature review primarily draws from studies available in the PubMed and Scopus databases on TBM regimens, focusing on publications that evaluate higher doses or novel drug therapies. Key search terms included "tuberculous meningitis," "anti-tuberculosis therapy," and "novel treatment regimens." Results: Findings suggest that while standard tuberculosis (TB) regimens are effective for pulmonary TB, they may be suboptimal for TBM due to limited CNS drug penetration. Recent investigations propose higher drug doses and novel medications to enhance efficacy in TBM treatment. Conclusion: The review highlights the need for TBM-specific treatment regimens with optimized dosing and new drug formulations to improve patient outcomes. Further research is needed to validate these emerging therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.